A unit of Takeda Pharmaceutical Co. Ltd. has asked a federal judge to toss a $155 million jury verdict last month finding that it had infringed a patent for Bayer AG’s hemophilia treatment.

In a court filing Friday, Baxalta Inc. argued that Bayer’s patent was invalid and that the German-based pharmaceutical firm had presented no evidence to support the jury’s damages award. According to Baxalta, Bayer never disclosed to the public how to make and use the full scope of its claims, and the drug’s inventors testified at trial that they did not know how to make a key feature of the drug that was covered by the patent.